New strategies in refractory and recurrent neuroblastoma: Translational opportunities to impact patient outcome

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2423-2428

  Cole, Kristina A ^a,b   Maris, John M ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALISERTIB; CRIZOTINIB; GANGLIOSIDE GD2; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MOLECULAR THERAPY AGENT; MONOCLONAL ANTIBODY; NORADRENALIN DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TEMOZOLOMIDE; TUMOR MARKER;

ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; AURORA KINASE A GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EPIGENETICS; GENE MUTATION; GENE TARGETING; GENE TRANSLOCATION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LUNG SMALL CELL CANCER; NEUROBLASTOMA; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT CANCER; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

CHILD; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84860538693     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1409     Document Type: Article

References (53)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.
2. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
3. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010;28:2625-34.
4. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73. (Pubitemid 29480654)
5. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005;6:649-58. (Pubitemid 41222755)
6. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16:953-65. (Pubitemid 28108728)
7. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Children's Oncology Group. Anti-GD2 antibody with GMCSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.
8. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8. (Pubitemid 14227614)
9. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4. (Pubitemid 14106392)
10. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6. (Pubitemid 16216827)
11. Abel F, Dalevi D, Nethander M, Jörnsten R, De Preter K, Vermeulen J, et al. A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int 2011;11:9.
12. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98:1193-203. (Pubitemid 44390990)
13. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16:1532-41.
14. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28:3506-15.
15. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-91. (Pubitemid 39330995)
16. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
17. George RE, Sanda T,Hanna M, Fröhling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8.
18. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4.
19. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70.
20. Weiser D, Laudenslager M, Rappaport E, Carpenter E, Attiyeh E, Diskin S, et al. Stratification of patients with neuroblastoma for targeted ALK therapy. J Clin Oncol 2011;29;9514.
21. Kwak EL, Bang YJ, Camidge DR, ShawAT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med 2010;363:1693-703.
22. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009;15:67-78.
23. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34.
24. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist 2009;14:83-91.
25. Singleton JR, Randolph AE, Feldman EL. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 1996;56:4522-9. (Pubitemid 26330465)
26. Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, et al. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 2006;12:6772-80. (Pubitemid 44876847)
27. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010;54:921-6.
28. Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, et al. Phase I study of temsirolimus in pediatric patients with recurrent/ refractory solid tumors. J Clin Oncol 2011;29:2933-40.
29. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 2011;108:3336-41.
30. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2011 Aug 15. [Epub ahead of print].
31. Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011;71:1385-95.
32. Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010;142:218-29.
33. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, et al. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med 2012;4:115ra3.
34. Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011;29:208-13.
35. Lipsitz E, Nguyen H, Zhao H, Ecsedy J, Maris J, Adamson PC, et al. Modeling MLN8237, an aurora kinase A inhibitor, with irinotecan (IRN) and temozolamide (TMZ) in neuroblastoma (NB). J Clin Oncol 2010; 28:15s;10593.
36. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody- dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989;73:1936-41. (Pubitemid 19145127)
37. Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin- 2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol 1994;15:29-37. (Pubitemid 24005091)
38. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-40. (Pubitemid 18049879)
39. Cheung NK, Kushner BH, Yeh SD, Larson SM. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol 1998;12:1299-306. (Pubitemid 28239940)
40. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, et al. A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-7.
41. Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-80. (Pubitemid 28265055)
42. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, et al. Children's Oncology Group. A phase I clinical trial of the hu14.18- IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-9.
43. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/ refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010;28:4969-75.
44. Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2- expressing tumors. Curr Cancer Drug Targets 2010;10:200-9.
45. Sorkin LS, Otto M, Baldwin WM 3rd, Vail E, Gillies SD, Handgretinger R, et al. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 2010;149:135-42.
46. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-60. (Pubitemid 46596756)
47. More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, et al. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res 2011;17:2339-49.
48. 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study. J Clin Oncol 2011;29:9513.
49. Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998;77:2061-8. (Pubitemid 28263923)
50. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011;331:435-9.
51. Pugh T, Lawrence M, Sougnez C, Getz G, Attiyeh E, Hogarty M, et al. Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research. 2011 April 2-6; Orlando, FL. Philadelphia (PA): AACR, 2011. Abstract nr 4756.
52. Morozova O, Birol I, Corbett R, Mungall K, Attiyeh E, Asgharzadeh S, et al. Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research. 2011 April 2-6; Orlando, FL. Philadelphia (PA): AACR, 2011. Abstract nr 926.
53. Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A 2008;105:9751-6. (Pubitemid 352031372)